Even though we have determined that FANCD2 expression increases with brain tumour grade, it does not indicate if the FA pathway is active in these tumours and could contribute to chemotherapeutic resistance mechanisms [19, 20]. This evidence concerns the gene FANCD2 and neoplasm.